Industry leader brings deep expertise in international drug development, strategic leadership, and corporate partnering for biopharmaceutical companies.
Equities research analysts expect Humacyte, Inc. (NASDAQ:HUMA – Get Rating) to report sales of $260,000.00 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Humacyte’s earnings. The lowest sales estimate is $130,000.00 and the highest is $400,000.00. The company is expected to issue its next quarterly earnings report […]
Humacyte (NASDAQ:HUMA – Get Rating) was downgraded by investment analysts at Piper Sandler from an “overweight” rating to an “underweight” rating in a research report issued to clients and investors on Sunday, The Fly reports. Separately, Zacks Investment Research lowered Humacyte from a “buy” rating to a “hold” rating in a research report on Saturday, […]